Meanwhile, anti-PD-1/PD-L1 immunotherapy is the hotspot for advanced MIBC, and the response rate of immunotherapies is determined by various conditions, including tumor immunity and cancer cell immunogenicity [18, 19]. This evidence concerns the gene CD274 and cancer.